Guggenheim Capital’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $301K | Sell |
12,171
-35,455
| -74% | -$845K | ﹤0.01% | 1378 |
|
|
2025
Q4 | $1.11M | Buy |
47,626
+35,274
| +286% | +$786K | 0.01% | 899 |
|
|
2025
Q3 | $243K | Buy |
+12,352
| New | +$254K | ﹤0.01% | 1459 |
|
|
2024
Q4 | – | Sell |
-24,760
| Closed | -$492K | – | 1736 |
|
|
2024
Q3 | $492K | Sell |
24,760
-29,369
| -54% | -$544K | ﹤0.01% | 1415 |
|
|
2024
Q2 | $838K | Buy |
+54,129
| New | +$843K | 0.01% | 1203 |
|
|
2023
Q4 | – | Sell |
-68,988
| Closed | -$806K | – | 1888 |
|
|
2023
Q3 | $806K | Sell |
68,988
-4,626
| -6% | -$61.9K | 0.01% | 1201 |
|
|
2023
Q2 | $989K | Buy |
73,614
+10,551
| +17% | +$152K | 0.01% | 1162 |
|
|
2023
Q1 | $1.05M | Buy |
63,063
+40,990
| +186% | +$676K | 0.01% | 1161 |
|
|
2022
Q4 | $411K | Buy |
22,073
+9,871
| +81% | +$152K | ﹤0.01% | 1567 |
|
|
2022
Q3 | $157K | Buy |
+12,202
| New | +$145K | ﹤0.01% | 1818 |
|
|
2018
Q2 | – | Sell |
-25,067
| Closed | -$59K | – | 2416 |
|
|
2018
Q1 | $59K | Buy |
25,067
+1,551
| +7% | +$5.15K | ﹤0.01% | 2699 |
|
|
2017
Q4 | $91K | Sell |
23,516
-3,728
| -14% | -$12.3K | ﹤0.01% | 2609 |
|
|
2017
Q3 | $68K | Buy |
27,244
+18
| +0.1% | +$49 | ﹤0.01% | 2676 |
|
|
2017
Q2 | $74K | Buy |
27,226
+2,242
| +9% | +$4.68K | ﹤0.01% | 2713 |
|
|
2017
Q1 | $49K | Buy |
24,984
+3,649
| +17% | +$4.65K | ﹤0.01% | 2736 |
|
|
2016
Q4 | $22K | Hold |
21,335
| – | – | ﹤0.01% | 2842 |
|
|
2016
Q3 | $23K | Sell |
21,335
-260
| -1% | -$234 | ﹤0.01% | 2815 |
|
|
2016
Q2 | $15K | Sell |
21,595
-1,760
| -8% | -$1.42K | ﹤0.01% | 2823 |
|
|
2016
Q1 | $27K | Sell |
23,355
-5,789
| -20% | -$8.98K | ﹤0.01% | 2812 |
|
|
2015
Q4 | $72K | Buy |
29,144
+9,665
| +50% | +$27.7K | ﹤0.01% | 2868 |
|
|
2015
Q3 | $59K | Sell |
19,479
-417
| -2% | -$1.8K | ﹤0.01% | 2838 |
|
|
2015
Q2 | $82K | Buy |
19,896
+8,541
| +75% | +$34K | ﹤0.01% | 2918 |
|
|
2015
Q1 | $49K | Buy |
+11,355
| New | +$40.9K | ﹤0.01% | 2931 |
|
|
2014
Q3 | – | Sell |
-17,744
| Closed | -$45K | – | 3011 |
|
|
2014
Q2 | $45K | Sell |
17,744
-1,774
| -9% | -$3.79K | ﹤0.01% | 3092 |
|
|
2014
Q1 | $44K | Buy |
19,518
+4,436
| +29% | +$9.28K | ﹤0.01% | 3151 |
|
|
2013
Q4 | $29K | Buy |
15,082
+895
| +6% | +$1.81K | ﹤0.01% | 3102 |
|
|
2013
Q3 | $43K | Buy |
14,187
+1,883
| +15% | +$3.17K | ﹤0.01% | 2952 |
|
|
2013
Q2 | $11K | Buy |
+12,304
| New | +$9.85K | ﹤0.01% | 3011 |
|
Other funds holding CPRX
VCM
DM
VPM
Guggenheim Capital's CPRX Position: Q1 2026 in Review
Guggenheim Capital reduced its Catalyst Pharmaceutical (CPRX) stake by 74% in Q1 2026, selling an estimated $845K and leaving 12,171 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #1378.
Guggenheim Capital first reported a position in CPRX in Q2 2013 and has held it in 28 quarters since. The position peaked at $1.11M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Guggenheim Capital held 12,171 shares of Catalyst Pharmaceutical worth $301K as of Q1 2026.
- Guggenheim Capital sold 35,455 Catalyst Pharmaceutical shares in Q1 2026, an estimated $845K.
- Catalyst Pharmaceutical made up ﹤0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1378 holding.
- Guggenheim Capital first reported a position in Catalyst Pharmaceutical in Q2 2013 and has held it in 28 quarters since.
- Guggenheim Capital's Catalyst Pharmaceutical position peaked at $1.11M in Q4 2025.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.